AlzeCure Pharma has announced the appointment of Märta Segerdahl, MD, PhD, Associate professor, as Chief Medical Officer (CMO).
Segerdahl will be a member of AlzeCure’s executive management team and succeeds An van Es-Johansson, MD, currently CMO and Head of Development, and previously member of the Board, who will continue working for AlzeCure as an advisor.
“We are delighted to have Märta joining our team. Her expertise in CNS and solid experience in leading clinical development and building development organizations will strengthen our clinical capacity as we are now maturing the clinical portfolio. Her experience from both big pharma and biotech will also be instrumental in our business development efforts and partnering discussions,” says Martin Jönsson, CEO of AlzeCure Pharma.
More than 15 years of industry experience from both big pharma and small biotech
Segerdahl will take on the position as CMO on April 1 and will have the overall medical responsibility for AlzeCures’s drug development candidates and will lead the clinical development organization. She has more than 15 years of industry experience from both big pharma and small biotech, with various senior positions in pharmaceutical drug development, focusing on neuroscience. Recent positions include CMO at Asarina Pharma ApS, Chief Medical Specialist at Lundbeck A/S, Senior Medical Director Medical Intelligence at Grünenthal GmbH, and Global Medical Science Director Emerging Cognition at AstraZeneca.
“I am thrilled to join the AlzeCure team at this important time in the company’s development. I hope to be able to apply my many years of clinical experience within neurology and pain as well as my clinical drug development skills to progress AlzeCure’s drug candidates to the next level,” says Segerdahl.
Photo of Märta Segerdahl: AlzeCure